Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
Gold Runner Exploration Completes 2026 Option Payment For Falcon Property Near Elko Nevada And Provides Update On Exploration Plans
